Revenue, 2025

USD 12.76 Billion

Forecast, 2035

USD 27.40 Billion

CAGR, 2026-2035

7.94%

Report Coverage

Global

Key Takeaways of Lateral Flow Assays Market

• Lateral flow assays sector pushed the market to USD 12.76 billion by 2025.
• Long-term projections show USD 27.40 billion valuation by 2035.
• Growth is expected at a steady CAGR of 7.94% in between 2026 to 2035.
• North America held approximately a 37% share in the global lateral flow assays market in 2025.
• Asia Pacific is expected to be the fastest-growing from 2026-2035.
• By product type, the kits & reagents segment held an approximate 82% share in the market in 2025.
• By product type, the readers/analyzers segment is expected to be the fastest growing at a notable CAGR during the forecast period.
• By technique type, the sandwich assays segment held approximately a 46% share in the market in 2025. 
• By technique type, the multiplex detection segment is expected to be the fastest growing during the forecast period.
• By application type, the infectious disease testing segment held approximately a 39% share in the market in 2025.
• By application type, the cardiac marker testing segment is expected to be the fastest growing during the forecast period.
• By sample type, the blood/serum/plasma segment held an approximate 42% share in the market in 2025.
• By sample type, the oral fluid/saliva segment is expected to be the fastest growing during the forecast period.
• By end user, the clinical/diagnostic laboratories segment held an approximate 38% share in the global lateral flow assays market in 2025.
• By end user, the home care/OTC segment is expected to be the fastest growing during the forecast period.

Lateral Flow Assays Market Trends for 2026

The global lateral flow assays market size was valued at US$ 12.76 billion in 2025 and is projected to grow to US$ 14.23 billion in 2026. Forecasts suggest it will reach approximately US$ 27.40 billion by 2035, registering a CAGR of 7.94% during the period.

The demand for lateral flow assays is increasing for the rapid, early, and accurate detection of various diseases, fertility testing, drug abuse screening, food safety, etc. This, in turn, is increasing their innovations by integrating with AI. A new set of rules and guidelines is also being introduced by the government to tackle the rising diseases and enhance food safety. This is increasing the development, collaborations, and launches of different types of these tools. Moreover, their demand in different regions is increasing. Thus, this promotes the market growth.

What is the Lateral Flow Assays Market?

The lateral flow assays (LFA) market covers rapid, point-of-care diagnostic devices that detect target analytes (antigens, antibodies, nucleic acids, biomarkers) in a sample, typically blood, urine, saliva, or swab, through capillary action on a nitrocellulose membrane. These tests are widely used in infectious disease diagnostics, pregnancy/fertility testing, cardiac marker detection, drug abuse screening, and veterinary diagnostics. Growth is driven by demand for decentralized, low-cost testing, technological advancements (quantitative LFAs, smartphone integration), rising prevalence of chronic and infectious diseases, and sustained post-COVID awareness for at-home and rapid diagnostics.

What are the Latest Government Initiatives in the Lateral Flow Assays Market?

Increasing government initiatives: To combat the growing diseases, various guidelines and rules are being introduced by the government. Moreover, to improve the health outcomes, new screening programs are also being conducted. This, in turn, is enhancing the detection of diseases and food safety testing.

For instance,

• In August 2025, to deal with waterborne diseases, new guidelines were released by the National Centre for Disease Control. Collaboration between the ministries to improve public health outcomes was also formed by these guidelines.
• In August 2025, to enhance food safety and urban standards, new rules were introduced for private food laboratories by the Ministry of Municipalities and Housing of Saudi Arabia. For food testing, along with their standard conditions measurements, these rules will be applied to the independent laboratories or as part of a conformity assessment body.

Trends and Future Outlook

• Rising Burden of Infectious Diseases: With the need for rapid screening of infectious diseases, the primary revenue driver, accounting for a vast majority of clinical test applications, is rising with infectious diseases.
• Broader Applications: Beyond clinical testing, Lateral Flow Assays are being developed to detect cancer biomarkers directly from biofluids, matching the concordance rates of gold-standard lab assays, and are expanding into veterinary medicine, food and beverage safety testing, and environmental monitoring.
• Consumer-Friendly Formats: Moving away from invasive blood draws, modern consumer-friendly Lateral Flow Assays utilize less invasive collection methods such as saliva, urine, or shallow nasal swabs. Most tests rely on the naked eye, using colorimetric changes to provide intuitive "yes/no" results.

What is the Use of AI in the Lateral Flow Assays Market?

The use of AI in lateral flow assays is increasing to enhance the accuracy of the tools. With the use of AI, the LFA results can be analyzed and scanned using a smartphone camera. This enhances the remote diagnosis. It also helps in providing real-time disease surveillance, as well as can be used for monitoring chronic diseases. They are also being used for the selection of antibodies for the LFA. They can analyze the performance of LFA as well as predict fast negative results.

Market Dynamics

Driver

Growing Point-of-Care Testing Demand

To deal with the growing diseases, the demand for point-of-care testing is increasing. This is increasing the use of the lateral flow assay. These tools offer fast results and can be used across various settings, such as home, ambulances, etc., enhancing the convenience of the patients. At the same time, they are being used for the detection of biomarkers for the management of chronic diseases. This is increasing their innovations for remote patient monitoring. Thus, this drives the lateral flow assays market growth.

Restraint

Lack of Sensitivity and Specificity

The sensitivity and specificity of these lateral flow assays are considered to be low. This decreases the accuracy of the tools. This, in turn, can lead to false negatives are false positives. Thus, this is increasing the regulatory complexities and increasing the use of molecular diagnostics (PCR). This restrains the use of LFA.

Opportunity

Rising Development of Multiplex and Eco-Friendly LFAs

The demand for the use of multiplex detection is increasing in the healthcare sector. This, in turn, is driving the development of the same for the detection of different diseases. Therefore, innovation for the detection of cancer, cardiac, or other biomarkers is increasing for complex diagnostics. At the same time, the growing environmental concerns are increasing the use of biodegradable and non-toxic materials in LFA. Moreover, new saliva-based testing re being developed due to non-invasiveness. Hence, this is promoting the lateral flow assays market growth.

For instance,

• In July 2025, the Radially Compartmentalised Paper Chip (RCP-Chip), which is a paper-based diagnostic tool detecting diseases within 10 minutes, was revealed by at New York University Abu Dhabi (NYUAD), by the team of scientists. This tool can be used for the detection of infectious diseases.

Executive Summary Table

Segmental Insights

By Product Type

Explanation

• Kits & Reagents support diagnostic testing and hold 82% and dominate due to essential role in lab workflows and high demand.
• Readers/Analyzers interpret test results and capture 10% but do not dominate as they are specialized and less widely adopted.
• Ancillary/Consumables provide supplementary lab tools and represent 8% but do not dominate due to secondary importance and limited use.

How the Kits & Reagents Segment Dominated the Lateral Flow Assays Market in 2025?

By product type, the kits & reagents segment led the market with approximately 82% share in 2025. The demand for kits and reagents increased due to their recurring use. Moreover, complete test kits for various applications were also provided. This contributed to the market growth.

By product type, the readers/analyzers segment is expected to show the fastest growth rate at a notable CAGR during the predicted time. Their use is increasing due to their portability and quantitative results. At the same time, they are being used with digital platforms. Thus, accurate results and interpretation are increasing their use.

By Technique Type

Explanation

• Sandwich Assays detect specific targets and hold 46% and dominate due to high sensitivity and widespread application in diagnostics.
• Competitive Assays measure analytes indirectly and capture 32% but do not dominate as they are less versatile than sandwich formats.
• Multiplex Detection identifies multiple targets simultaneously and represents 22% and is gaining momentum due to efficiency and emerging research needs.

Which Technique Type Segment Held the Dominating Share of the Lateral Flow Assays Market in 2025?

By technique type, the sandwich assays segment held the dominating share of approximately 46% in the market in 2025. They showed improved sensitivity. Thus, they were used in the detection of larger molecules with high specificity. They were also used in the detection of other infectious diseases.

By technique type, the multiplex detection segment is expected to show the highest growth during the predicted time. It offers simultaneous detection of multiple analytes. Moreover, it shows enhanced efficiency and is affordable. Thus, their use in the detection of infectious and chronic diseases is increasing.

By Application Type

Explanation

• Infectious Disease Testing detects pathogens and holds 39% and dominates due to high global demand and routine screening requirements.
• Pregnancy & Fertility Testing monitors reproductive health and captures 15% but does not dominate as it targets a specific population segment.
• Cardiac Marker Testing identifies heart-related conditions and holds 13% but does not dominate due to specialized clinical use.
• Drug of Abuse Screening detects substance use and represents 7% but does not dominate as it serves a niche regulatory and clinical need.
• Veterinary Diagnostics monitors animal health and captures 8% but does not dominate due to smaller market size compared to human diagnostics.
• Food Safety & Environmental Testing ensures contamination detection and holds 18% and is gaining momentum due to rising safety regulations and consumer awareness.

Why the Infectious Disease Testing Segment Dominated the Lateral Flow Assays Market?

By application type, the infectious disease testing segment led the market with approximately 39% share in 2025. The growing incidence of infectious diseases increased the demand for LFA kits. They were used for the detection of respiratory infections (COVID-19, influenza), HIV, malaria, dengue, etc. Thus, this enhanced the market growth.

The graph represents the rise in the percentage of emergency admissions due to respiratory infections in England in 2024. It indicates that there will be a rise in cases of respiratory infections. Hence, it increases the demand for the lateral flow assay for its effective detection and management. Thus, this in turn will ultimately promote the market growth.

By application type, the cardiac marker testing segment is expected to show the fastest growth rate during the upcoming years. For the early detection of cardiac disease, the use is increasing. Moreover, the growing demand for rapid MI diagnosis (troponin, CK-MB) is also contributing to the same.

By Sample Type

Explanation

• Blood/Serum/Plasma serves as the primary testing sample and holds 42% and dominates due to high reliability and widespread clinical use.
• Urine provides non-invasive diagnostic sampling and captures 23% but does not dominate as it has limited analyte range.
• Oral Fluid/Saliva offers convenient sample collection and holds 17% but does not dominate due to lower sensitivity and niche applications.
• Nasal/Throat Swabs detect respiratory pathogens and represent 18% and is gaining momentum due to rising infectious disease testing demand.

What Made Blood/Serum/Plasma the Dominant Segment in the Lateral Flow Assays Market in 2025?

By sample type, the blood/serum/plasma segment held the largest share of approximately 42% in the market in 2025. Different types of analytes were easily detected through these sample types. This, in turn, provided accurate results. Thus, they were widely used in hospitals and labs for various applications.

By sample type, the oral fluid/saliva segment is expected to show the highest growth during the upcoming years. They are preferred due to their non-invasive sampling procedures. This is increasing their use in infectious diseases and DOA tests. Thus, they are also being used for home testing.

By End user

Explanation

• Clinical/Diagnostic Laboratories perform specialized testing and hold 38% and dominate due to high sample volume and advanced infrastructure.
• Home Care/OTC provides at-home testing solutions and captures 25% and is gaining momentum due to rising consumer convenience and self-monitoring trends.
• Physician Offices/Urgent Care Centers offer point-of-care diagnostics and hold 15% but do not dominate as testing volume is limited.
• Veterinary Clinics & Animal Health Centers conduct animal diagnostics and represent 10% but do not dominate due to smaller market size.
• Forensic & Workplace Testing Sites ensure compliance and safety and capture 12% but do not dominate as usage is niche and situational.

Why Did the Clinical/Diagnostic Laboratories Segment Dominate in the Lateral Flow Assays Market in 2025?

By end user, the clinical/diagnostic laboratories segment dominated the global market with approximately 38% share in 2025. The use of LFA increased in these laboratories due to higher volumes of patients. Different types of diseases were detected with its use. Moreover, they were also used for fertility and drug testing. Thus, this promoted the market growth.

By end user, the home care/OTC segment is expected to show the fastest growth rate during the forthcoming years. The LFA kits are being used for COVID self-tests, pregnancy kits, and chronic disease monitoring. Moreover, the OTC availability is increasing its adoption rates. Thus, this is enhancing the patient's convenience and comfort.

Regional Analysis

Why is There a Rise in the Demand for Lateral Flow Assay in Different Regions?

North America Driven by Growing Adoption Rates

North America dominated the lateral flow assays market share by 37% in 2025. The healthcare sector in North America is well-developed, which has increased the use of the lateral flow assay. They were used for the rapid detection of infectious and chronic diseases. Thus, this contributed to the market growth.

U.S. Lateral Flow Assays Market Trends

The U.S. consists of well-developed industries. These industries are developing various types of lateral flow assays. At the same time, the use in food testing as well as veterinary diagnostics is increasing. Thus, these developments are supported by the regulatory bodies and the government and are available at various OTC channels.

Canada Lateral Flow Assays Market Trends

To deal with the growing infectious disease in Canada, the use of LFA is increasing. At the same time, the growing public health screening programs are increasing their demand. This, in turn, is increasing their development for home care and clinical applications. These are supported by the healthcare investments.

Rising Infectious Disease Burden Drives Asia Pacific

Asia Pacific is expected to host the fastest-growing lateral flow assays market during the forecast period. Asia Pacific is facing a rise in the incidence of infectious diseases. This is increasing the demand for LFA. Thus, this enhances the market growth.

China Lateral Flow Assays Market Trends

Due to the presence of large populations in China, the risk of diseases increases. Thus, this drives the development of new LFA tools. The industries are utilizing advanced technologies to enhance their sensitivity and specificity. Moreover, the growing OTC retail diagnostics are also contributing to the same.

India Lateral Flow Assays Market Trends

The growing government-led screening programs are increasing awareness within the population. This, in turn, is increasing the research and development for formulating new LFA tools. Furthermore, the increasing healthcare access is increasing their adoption rates. The government initiatives are also encouraging their adoption.

Increasing Investments Boost Europe

Europe is expected to grow significantly in the lateral flow assays market during the forecast period. The presence of the advanced health care sector is increasing the investments for the development of new LFA tools. At the same time, growing home testing is increasing the demand for LFA. Thus, this is promoting the market growth.

Germany Lateral Flow Assays Market Trends

The industries as well as institutions in Germany are focusing on the development of advanced LFA kits. This, in turn, is increasing the interest in their research and development for new diagnostic kits. Thus, various investments and funding are being provided by the government.

UK Lateral Flow Assays Market Trends

The rising incidences of communicable diseases are increasing the demand for the LFA. At the same time, these tools are also being used for food and environmental testing. Thus, this is enhancing their development and innovations. Moreover, new initiatives by the government are accelerating their adoption.

Demand for POC Testing Fuels South America

South America is expected to grow significantly in the lateral flow assays market during the forecast period, due to growing demand for rapid point-of-care testing options. The growth in infectious diseases and health awareness are also increasing the use of lateral flow assays, where the growing government screening programs are also increasing their demand, promoting the market growth.

Brazil Lateral Flow Assays Market Trends

The growing infectious disease burden in Brazil is increasing the use of lateral flow assays for their early and acute detection. Additionally, growing demand for rapid and portable diagnostic devices is also increasing their use for self-testing, where the growing healthcare investments and health awareness are also increasing their advancements and adoption rates, respectively.

Growing Disease Burden Promotes MEA

MEA is expected to show lucrative growth in the lateral flow assays market during the forecast period, due to growing incidences of infectious diseases. The expanding healthcare, growing government initiatives, and demand for affordable diagnostic methods are increasing the use of lateral flow assays, where the increasing health awareness is also driving their demand, enhancing the market growth.

Saudi Arabia Lateral Flow Assays Market Trends

Saudi Arabia is experiencing a growth in the healthcare infrastructure, where the growing government initiatives are also promoting the adoption of lateral flow assays for early detection of various infectious diseases. The growing shift towards home-based care is also increasing their demand, where technological advancements are accelerating its innovations.

Market Ecosystem Analysis

Lateral Flow Assays Market Value Chain Analysis

R&D

• The R&D for the lateral flow assays focuses on integration of nanomaterial labels and smartphone-based digital readers, along with enhancement of sensitivity and quantification.
• Key players: Becton Dickinson (BD), Abbott, Meridian Bioscience.

Clinical Trials and Regulatory Approvals

• The clinal specificity, analytical sensitivity, and cross-reactivity are evaluated in the clinical trials and regulatory approvals of the lateral flow assays.
• Key players: Becton Dickinson (BD), Abbott, Roche.

Formulation and Final Dosage Preparation

• The formulation and final dosage preparation involve the precise impregnation of reagent onto nitrocellulose membranes and stabilization of antibody-gold conjugates within the pad architecture.
• Key players: Abbott, Merck Millipore, Danaher.

Distribution to Hospitals, Pharmacies

• The cold chain logistics and multi-tiered wholesale networks are responsible for the distribution of the lateral flow assays to the hospitals and pharmacies.
• Key players: McKesson, Henry Schein, Cardinal Health.

Patient Support and Services

• The digital result reporting apps, 24/7 technical hotlines, and telehealth integration are provided in the patient support and services of the lateral flow assays.
• Key players: Abbott, Roche, Cue Health.

Top Companies in the Lateral Flow Assays Market

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• BD (Becton, Dickinson and Company)
• QuidelOrtho Corporation
• Siemens Healthineers
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Danaher Corporation
• Merck KGaA
• bioMérieux SA
• OraSure Technologies, Inc.
• Hologic, Inc.
• Chembio Diagnostics, Inc.
• Innova Medical Group
• ACON Laboratories, Inc.
• Trinity Biotech plc
• SD Biosensor, Inc.
• Access Bio, Inc.
• Ellume Limited
• Abingdon Health plc

Market Share Influence Assessment

Competitive Landscape

Swot Analysis

Strengths

• User-Friendly Design: The company has designed with intuitive, step-by-step formats, minimizing the need for highly trained medical professionals to administer the tests.
• Cost-Effectiveness: The company is eliminating central-lab logistics and lowering overall per-test costs; both manufacturing and testing costs are significantly lower compared to central-lab-based alternatives.

Weaknesses

• Lower Sensitivity: It exhibits lower analytical sensitivity and specificity than centralized lab assays (PCR, ELISA) because they rely on rapid, equipment-free capillary flow. 
• Qualitative/Semi-Quantitative Output: Traditional Lateral Flow Assays yield binary results limited to binary (yes/no) readouts when interpreted visually, rendering them insufficient for tracking fluctuating biomarker concentrations. To overcome this and achieve semi-quantitative or fully quantitative outputs, the industry is shifting toward several enhanced diagnostic strategies.

Opportunities

• Smartphone & AI Integration: It eliminates subjective human error and enables instant, quantitative results. Instead of relying on the naked eye to read faint or ambiguous test lines, users can capture the strip on a phone camera for objective, algorithm-driven analysis and seamless digital tracking. 
• Multiplex Testing: By integrating spatial coding and advanced nanoparticles, these strips eliminate the need for multiple tests. Paired with smartphone-based readers and digital health apps, this vastly improves data interpretation, connectivity, and tracking. 

Threats

• Intense Competition: They are pushing industry boundaries by offering rapid, cost-effective, and highly accurate decentralized alternatives to traditional gold-standard methods.
• Pricing Pressures: Commoditization of rapid tests (particularly post-pandemic) is compressing profit margins for manufacturers. The company is shifting strategies toward higher-value menus, digital connectivity, and decentralized testing platforms to survive.

Latest Announcements by Industry Leaders

In June 2025, after announcing the collaboration between Fujirebio and Stanford Medicine, the CEO and president of Fluxus, Inc. (wholly-owned subsidiary of Fujirebio), Dr. Peter Wagner, stated that, by merging the world-renowned research of Stanford with global IVD expertise of Fujirebio and ultrasensitive detection systems of Fluxus, they will take a step toward their mission to improve public health globally. Moreover, they were pleased to work with the prestigious infectious disease experts of Stanford University.

Recent Developments in the Lateral Flow Assays Market

• In August 2025, the Chikungunya IgM/IgG Rapid Test was launched by Anbio Biotechnology. The fast and reliable qualitative detection of Chikungunya-specific antibodies present in blood, plasma, or serum can be achieved by it, as it is based on immunochromatographic technology.
• In June 2025, the Lumipulse G sTREM2 assay was launched by H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio. The soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) within blood and human cerebrospinal fluid  (CSF) can be quantitatively measured in 35 minutes, and is a CLEIA (chemiluminescent enzyme immunoassay) assay available for Research Use Only (RUO).

Segments Covered in the Report

By Product Type

• Kits & Reagents
• Readers/Analyzers
• Ancillary/Consumables

By Technique

• Sandwich Assays
• Competitive Assays
• Multiplex Detection

By Application

• Infectious Disease Testing
• Pregnancy & Fertility Testing
• Cardiac Marker Testing
• Drug of Abuse Screening
• Veterinary Diagnostics
• Food Safety & Environmental Testing

By Sample Type

• Blood/Serum/Plasma
• Urine
• Oral Fluid/Saliva
• Nasal/Throat Swabs

By End User

• Clinical/Diagnostic Laboratories
• Home Care/OTC
• Physician Offices/Urgent Care Centers
• Veterinary Clinics & Animal Health Centers
• Forensic & Workplace Testing Sites

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait